Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021

Rhea-AI Summary

ReShape Lifesciences Inc. (OTCQB:RSLS) will announce its fourth quarter and full year 2020 financial results on March 10, 2021, after market close. A webinar is scheduled for the same day at 4:30 p.m. E.T to discuss these results. The company's innovative medical devices target obesity and metabolic diseases, including the FDA-approved Lap-Band and the investigational ReShape Vest. These solutions provide minimally invasive weight-loss options, enhancing patient care without altering anatomy. For more details, visit the Investor Relations page.

Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T

SAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it will report its fourth quarter and full year 2020 financial and operational results on Wednesday, March 10, 2021 after the close of the U.S. financial markets.

Management will post a webinar to discuss ReShape's financial results at 4:30 p.m. ET that same day. The link to the webinar will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/.

About ReShape Lifesciences Inc.

ReShape Lifesciences is America's premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and associated program provide minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps obese and morbidly obese patients with rapid weight loss without permanently changing patient anatomy. The recently launched ReShapeCare™ Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time.

Company Contact:
Thomas Stankovich
Chief Financial Officer
ReShape Lifesciences Inc.
949-276-6042
tstankovich@ReShapeLifesci.com

Investor Contact:
James Salierno
Vice President
The Ruth Group
646-536-7028
jsalierno@theruthgroup.com

SOURCE: ReShape Lifesciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/633855/Reshape-Lifesciences-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-and-Operational-Results-on-Wednesday-March-10-2021

FAQ

What are the key details of ReShape Lifesciences' financial report on March 10, 2021?

ReShape Lifesciences will report its fourth quarter and full year 2020 financial results on March 10, 2021, after market close.

At what time is the ReShape Lifesciences webinar scheduled?

The webinar to discuss ReShape Lifesciences' financial results is scheduled for March 10, 2021, at 4:30 p.m. E.T.

Where can I find the webinar link for ReShape Lifesciences' financial results?

The webinar link will be available on the Investor Relations page of the ReShape Lifesciences website.

What is the focus of ReShape Lifesciences' products?

ReShape Lifesciences focuses on developing minimally invasive medical devices for treating obesity and metabolic diseases.

What notable products does ReShape Lifesciences offer?

ReShape Lifesciences offers the FDA-approved Lap-Band and the investigational ReShape Vest, among other weight-loss solutions.